NAMS vs SENS: fair value comparison
NewAmsterdam Pharma Company N.V. and Senseonics Holdings, Inc. · Updated 2026-10-19
NAMS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SENS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NAMS currently ranks higher by quality score.
| NAMS | SENS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $19.83 | $7.77 |
| 12-month range | $19.83–$41.45 | $4.86–$10.34 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #137 of 301 Healthcare | #138 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: NAMS fair value analysis · SENS fair value analysis